Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

The association between COPD and heart failure risk: a review

Authors de Miguel Díez J, Chancafe Morgan J, Jiménez García R

Published Date June 2013 Volume 2013:8 Pages 305—312

DOI http://dx.doi.org/10.2147/COPD.S31236

Received 28 February 2013, Accepted 12 April 2013, Published 28 June 2013

Javier de Miguel Díez,1 Jorge Chancafe Morgan,1 Rodrigo Jiménez García2

1Pulmonology Department, Gregorio Maranon University Hospital, Complutense University of Madrid, Madrid, Spain; 2Preventive Medicine and Public Health Teaching and Research Unit, Department of Health Sciences, Rey Juan Carlos University, Madrid, Spain

Abstract: Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective ß1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled ß2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.

Keywords: chronic obstructive pulmonary disease, heart failure

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Determinants and predictors of the cost of COPD in primary care: A Spanish perspective

Javier de Miguel Diez, Pilar Carrasco Garrido, Marta García Carballo, Angel Gil de Miguel, Javier Rejas Gutierrez, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:701-712

Published Date: 2 September 2008

Readers of this article also read:

The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

Zhang SD, McCrudden CM, Meng C, Lin Y, Kwok HF

OncoTargets and Therapy 2015, 8:835-843

Published Date: 15 April 2015

The effects of amlodipine and platelet rich plasma on bone healing in rats

Atalay Y, Bozkurt MF, Gonul Y, Cakmak O, Agacayak KS, Köse I, Hazman O, Keles H, Turamanlar O, Eroglu M

Drug Design, Development and Therapy 2015, 9:1973-1981

Published Date: 7 April 2015

Adipose tissue-secreted miR-27a promotes liver cancer by targeting FOXO1 in obese individuals

Sun B, Li J, Shao D, Pan Y, Chen Y, Li S, Yao X, Li H, Liu W, Zhang M, Zhang X, Chen L

OncoTargets and Therapy 2015, 8:735-744

Published Date: 7 April 2015

The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo

Wang C, Wang X, Zhong T, Zhao Y, Zhang WQ, Ren W, Huang D, Zhang S, Guo Y, Yao X, Tang YQ, Zhang X, Zhang Q

International Journal of Nanomedicine 2015, 10:2229-2248

Published Date: 19 March 2015

The effect of comorbidities on COPD assessment: a pilot study

Weinreich UM, Thomsen LP, Bielaska B, Jensen VH, Vuust M, Rees SE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:429-438

Published Date: 25 February 2015

Unilateral transient mydriasis and ptosis after botulinum toxin injection for a cosmetic procedure

Akkaya S, Kökcen HK, Atakan T

Clinical Ophthalmology 2015, 9:313-315

Published Date: 12 February 2015

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets

Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, Lee M, Seo JW, Park ES

Drug Design, Development and Therapy 2015, 9:695-706

Published Date: 30 January 2015

Managing comorbidities in COPD

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:95-109

Published Date: 7 January 2015

Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease

Ito K, Colley T, Mercado N

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:641-652

Published Date: 21 September 2012